Computer-aided drug design plays a vital role in drug discovery and development, and has become an indispensable tool in the pharmaceutical industry. As molecular databases of compounds and target structures are becoming larger and more and more computational screening approaches are available, there is an increased need in compute power and more complex workflows. Thus artificial intelligence gains a great attention in pharmaceutical application scenarios. Whether analyzing small molecules, peptides, proteins, oligonucleotides or antibodies, MedAI provides full service and strategic support for companies seeking to apply In Silico Drug Discovery methods. We have access to industry standard hardware and software to apply computational chemistry, molecular simulations, and chemical informatics methods to your projects. Our team will work with you to design experiments and get the results you need to make critical decisions and advance your projects.
Figure 1 In Silico Drug Discovery
Our AI drug discovery (AIDD) platform can generate new chemical entities utilizing accumulated experimental data, pharmacophore models and machine learning techniques. We also focus on the current methodological strategies in computer-aided drug discovery and design. Our team can perform fast and accurate in silico screening of drug candidate compounds, target profiling, compound structure scoring in de novo design, and other related calculations. These drug discovery services include but not limited to:
Our integrated drug discovery approach enables an efficient navigation of the early discovery process, spanning hit identification, hit-to-lead, and lead optimization.
MedAI has the full capability set to help you with your In Silico Drug Discovery needs. Our services can be contracted under confidentiality terms as well as other specific conditions agreed with the customer. Please contact us for more details.
Tech Trends in Artificial Intelligence What's up, what's down, what lies ahead, only found in MedAI!